MRKR News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

MR

Mkt Cap

$17.3M

Volume

1.13M

Next Earnings

November 12th

Loading chart

MR

MRKRMarker Therapeutics, Inc. Common Stock

MRKR

Pay with—

Available Balance0.00

MR

Mkt Cap

$15.3M

Volume

1.13M

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

All You Need to Know About MARKER THERAPEUTICS (MRKR) Rating Upgrade to Strong BuyMarker Therapeutics (MRKR) has been upgraded to a Zacks Rank #1 (Strong Buy) rating due to rising earnings estimates. The company's consensus estimate has increased 45.3% over the past three months, positioning it in the top 5% of Zacks-covered stocks. The upgrade reflects an improving business outlook that could drive near-term stock price appreciation.Zacks Investment Research · Oct 16, 2026

New Strong Buy Stocks for October 16thZacks has added five stocks to its Strong Buy list based on increasing consensus earnings estimates over the last 60 days. The stocks span energy, technology distribution, immuno-oncology, biopharmaceutical, and chemical manufacturing sectors, with earnings estimate increases ranging from 3.5% to 30.6%.Zacks Investment Research · Oct 16, 2026

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment ConferenceMarker Therapeutics announced CEO Dr. Juan Vera will participate in a fireside chat at the H.C. Wainwright conference on September 10, 2025, discussing their Multi-Antigen Recognizing (MAR) T cell platform and recent clinical developments.GlobeNewswire Inc. · Aug 28, 2025

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed LymphomaMarker Therapeutics reported promising results from its Phase 1 APOLLO study of MT-601, a multi-antigen T cell therapy for lymphoma. The study showed 66% objective response rates in Non-Hodgkin Lymphoma patients, with 50% achieving complete response and a favorable safety profile.GlobeNewswire Inc. · Aug 26, 2025

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with LymphomaMarker Therapeutics and Cellipont Bioservices have announced a collaboration to advance the cGMP manufacturing of MT-601, Marker's multi-antigen recognizing T cell therapy for lymphoma patients. The collaboration aims to accelerate clinical supply and lay the foundation for a potential pivotal trial and commercial readiness.GlobeNewswire Inc. · Jun 17, 2025

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology SummitMarker Therapeutics, a clinical-stage immuno-oncology company, announced that its President and CEO will present at the Citizens JMP Hematology and Oncology Summit on December 2, 2024. The presentation will provide an overview of the company's technology and clinical developments.GlobeNewswire Inc. · Nov 26, 2024

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesPreliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO studyGlobeNewswire Inc. · May 15, 2024

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, CanadaGlobeNewswire Inc. · Apr 8, 2024

Marker Therapeutics Reports Year-End 2023 Corporate and Financial ResultsLead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following CAR T relapseGlobeNewswire Inc. · Mar 25, 2024

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceHOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference. This conference will be held virtually on March 26, 2024.GlobeNewswire Inc. · Mar 22, 2024

to start trading

MR

MRKRMarker Therapeutics, Inc. Common Stock

MRKR

Pay with—

Available Balance0.00

Your PositionYou don't own any MRKR yet.

Related Tickers

Earnings